PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 29277762
OWN - NLM
STAT- MEDLINE
DCOM- 20180101
LR  - 20180104
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 1
DP  - 2018 Jan
TI  - Highly Activated PD-1/PD-L1 Pathway in Gastric Cancer with PD-L1 Expression.
PG  - 107-112
AB  - BACKGROUND: A recent study demonstrated that immune-checkpoint molecules are
      associated with tumoral immune evasion. MATERIALS AND METHODS: Programmed cell
      death protein 1 (PD-1) expression on CD4(+) and CD8(+) T-cells obtained from
      gastric cancer tissue was evaluated by multicolor flow cytometry.
      Immunohistochemical staining was also performed to evaluate programmed cell death
      ligand-1 (PD-L1) expression on gastric cancer cells. RESULTS: There were
      statistically significant correlations between PD-L1 expression and age,
      histology, tumor size, depth of invasion, lymph node metastasis, lymphatic vessel
      invasion, venous invasion, and disease stage. The 5-year survival rates of
      patients with and without PD-L1-positive tumors were 48.9% and 80.7%,
      respectively, and the difference was statistically significant. Multivariate
      analysis indicated that PD-L1 expression was an independent prognostic indicator.
      The frequency of PD-1-positive CD4(+) and CD8(+) T-cells from gastric cancer
      tissue with PD-L1 expression was significantly more than that from gastric cancer
      tissue without PD-L1 expression. CONCLUSION: PD-L1 expression was related to a
      poor prognosis in patients with gastric cancer. Furthermore, PD-1 expression on
      T-cells was up-regulated in patients with tumors with PD-L1 expression.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Saito, Hiroaki
AU  - Saito H
AD  - Department of Surgery, Division of Surgical Oncology, School of Medicine, Tottori
      University Faculty of Medicine, Yonago, Japan [email protected]
FAU - Kono, Yusuke
AU  - Kono Y
AD  - Department of Surgery, Division of Surgical Oncology, School of Medicine, Tottori
      University Faculty of Medicine, Yonago, Japan.
FAU - Murakami, Yuki
AU  - Murakami Y
AD  - Department of Surgery, Division of Surgical Oncology, School of Medicine, Tottori
      University Faculty of Medicine, Yonago, Japan.
FAU - Shishido, Yuji
AU  - Shishido Y
AD  - Department of Surgery, Division of Surgical Oncology, School of Medicine, Tottori
      University Faculty of Medicine, Yonago, Japan.
FAU - Kuroda, Hirohiko
AU  - Kuroda H
AD  - Department of Surgery, Division of Surgical Oncology, School of Medicine, Tottori
      University Faculty of Medicine, Yonago, Japan.
FAU - Matsunaga, Tomoyuki
AU  - Matsunaga T
AD  - Department of Surgery, Division of Surgical Oncology, School of Medicine, Tottori
      University Faculty of Medicine, Yonago, Japan.
FAU - Fukumoto, Yoji
AU  - Fukumoto Y
AD  - Department of Surgery, Division of Surgical Oncology, School of Medicine, Tottori
      University Faculty of Medicine, Yonago, Japan.
FAU - Osaki, Tomohiro
AU  - Osaki T
AD  - Department of Surgery, Division of Surgical Oncology, School of Medicine, Tottori
      University Faculty of Medicine, Yonago, Japan.
FAU - Ashida, Keigo
AU  - Ashida K
AD  - Department of Surgery, Division of Surgical Oncology, School of Medicine, Tottori
      University Faculty of Medicine, Yonago, Japan.
FAU - Fujiwara, Yoshiyuki
AU  - Fujiwara Y
AD  - Department of Surgery, Division of Surgical Oncology, School of Medicine, Tottori
      University Faculty of Medicine, Yonago, Japan.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (B7-H1 Antigen)
RN  - 0 (CD274 protein, human)
RN  - 0 (PDCD1 protein, human)
RN  - 0 (Programmed Cell Death 1 Receptor)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - B7-H1 Antigen/*metabolism
MH  - CD4-Positive T-Lymphocytes/metabolism
MH  - CD8-Positive T-Lymphocytes/metabolism
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Programmed Cell Death 1 Receptor/*metabolism
MH  - Stomach Neoplasms/*metabolism
OTO - NOTNLM
OT  - *Gastric cancer
OT  - *PD-1
OT  - *PD-L1
OT  - *T-cells
EDAT- 2017/12/27 06:00
MHDA- 2018/01/02 06:00
CRDT- 2017/12/27 06:00
PHST- 2017/10/23 00:00 [received]
PHST- 2017/11/07 00:00 [revised]
PHST- 2017/11/10 00:00 [accepted]
PHST- 2017/12/27 06:00 [entrez]
PHST- 2017/12/27 06:00 [pubmed]
PHST- 2018/01/02 06:00 [medline]
AID - 38/1/107 [pii]
AID - 10.21873/anticanres.12197 [doi]
PST - ppublish
SO  - Anticancer Res. 2018 Jan;38(1):107-112. doi: 10.21873/anticanres.12197.